marked.bio

Company

BioNTech

4 active trials that select patients by a biomarker on marked.bio, across 5 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

pumitamig 3YL202 2DB-1303 1trastuzumab 1BNT116 1cemiplimab 1gotistobart 1osimertinib 1

Trials

4 of 5 trials shown

  1. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    Recruiting Phase 1/2 BioNTech Started 2025Primary completion 2028-03 NCT07070232

    YL202pumitamigitraconazoleparoxetine

    …est results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor

  2. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    Recruiting Phase 1/2 BioNTech Started 2025Primary completion 2028-11 NCT07111520

    YL202pumitamig

    …est results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).

    EGFR exon 19 deletion / L858RALK fusionROS1 fusionNon-small Cell Lung Cancer

  3. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    Recruiting Phase 1/2 BioNTech Started 2025Primary completion 2029-08 NCT06827236

    DB-1303trastuzumabpumitamig

    …s a documented history of HER2 expression consistent with the subgroup definitions (i.e., HER2-low, HER2-ultralow, HER2-null, HER2-positive, or TNBC) as per current American Society of Cli…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

  4. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    Recruiting Phase 1 BioNTech Started 2022Primary completion 2030-02 NCT05142189

    BNT116cemiplimabdocetaxelcarboplatinpaclitaxelgotistobartanti-B7-H3 antibody conjugated to topoisomerase I inhibitoranti-HER3 antibody conjugated to topoisomerase I inhibitorBispecific antibody for PD-L1 and VEGF-Aosimertinib FDA EUALK-inhibitor or RET-inhibitor

    Participants' NSCLC must have classical EGFR mutations, i.e., ex19Del or L858R.

    EGFR exon 19 deletion / L858RALK fusionRET fusion or mutationNon-Small Cell Lung Cancer